Investigational drug · Phase 3
ezetimibe FDC
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
18
Any phase or sponsor naming "ezetimibe FDC"
First trial start
2024
May 16, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ezetimibe FDC", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lipidemia
- Coronary Artery Disease
- Plaque, Atherosclerotic
- Type 2 Diabetes (T2DM)
- Metabolic Syndrome (MetS)
Approved drugs for the same conditions: Type 2 diabetes · Coronary artery disease and heart attack · Cardiovascular and metabolic · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ezetimibe FDC" as an intervention, largest first.
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07206472 · 2,120 participants (planned) · Start Mar 3, 2026 · Primary completion Nov 22, 2028
Drug: Combination of bempedoic acid and ezetimibe · For: Primary Hypercholesterolaemia; Mixed Dyslipidemia
Sites: Belo Horizonte, Brazil; Blumenau, Brazil; Caixias Do Sul, Brazil · 38 sites in all
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
NCT05546398 · 500 participants · Start Apr 22, 2022 · Primary completion Nov 17, 2022
Drug: Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab · For: Hypercholesterolemia; Mixed Dyslipidemia
Sites: Arnsberg, Germany; Bad König, Germany; Berlin, Germany · 63 sites in all
- Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)Pivotal-lookingCompleted
Organon and CoIndustry
NCT03768427 · 454 participants · Start May 27, 2019 · Primary completion Mar 17, 2021
Drug: Atorvastatin; Placebo for FDC EZ/Ator and 1 more · For: Hypercholesterolemia
Sites: Baotou, China; Beijing, China; Chongqing, China · 30 sites in all
- A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin TherapyPivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT03337308 · 382 participants · Start Oct 23, 2017 · Primary completion Jun 18, 2018
Drug: Bempedoic Acid; Ezetimibe and 1 more · For: Hyperlipidemias
Sites: Ames, Iowa; Nashua, New Hampshire; Statesville, North Carolina · 5 sites in all
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaquePivotal-lookingActive, not recruiting
NewAmsterdam PharmaIndustry
NCT06305559 · 300 participants (planned) · Start May 16, 2024 · Primary completion Nov 2027
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily · For: Lipidemia; Coronary Artery Disease; Plaque, Atherosclerotic
Sites: Hialeah, Florida
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromePivotal-lookingActive, not recruiting
NewAmsterdam PharmaIndustry
NCT07219602 · 300 participants (planned) · Start Dec 11, 2025 · Primary completion Mar 2028
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily; Obicetrapib 10 mg · For: Lipidemia; Type 2 Diabetes (T2DM); Metabolic Syndrome (MetS)
Sites: Sun City West, Arizona; La Jolla, California; Pomona, California · 55 sites in all
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-CPivotal-lookingCompleted
Esperion Therapeutics, Inc.Industry
NCT03531905 · 242 participants · Start May 9, 2018 · Primary completion Jun 18, 2019
Drug: Bempedoic acid + Ezetimibe FDC Oral Tablet; Ezetimibe 10 mg Oral Tablet and 2 more · For: Diabetes; Diabetes Mellitus, Type 2; Cholesterolemia
Sites: Lincoln, California; Miami, Florida; Louisville, Kentucky · 4 sites in all
- A Study to Determine the Bioequivalence of SCH 900068 Compared to Marketed Products (Protocol No. P07551)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01236430 · 200 participants · Start Feb 2011 · Primary completion Nov 2011
Drug: Ezetimibe; Ezetimibe/atorvastatin 10mg/10mg FDC and 3 more · For: Hyperlipidemia
- Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and DyslipidemiaPivotal-lookingCompleted
Yonsei UniversityAcademic, hospital or other
NCT04061824 · 150 participants · Start May 24, 2016 · Primary completion Dec 20, 2018
Drug: Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination)); Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin) · For: Hypertension; Dyslipidemias
Sites: Seoul, South Korea
- A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)Pivotal-lookingCompleted
Organon and CoIndustry
NCT02460159 · 135 participants · Start Jun 23, 2015 · Primary completion Dec 22, 2016
Drug: EZ 10 mg/Atorva 20 mg FDC; EZ 10 mg/Atorva 10 mg FDC · For: Hypercholesterolemia; Heterozygous Familial Hypercholesterolemia
Newest research
PubMed records naming it or its code names, newest first.
- Rationale and design of the REMBRANDT trial: A phase 3 study to evaluate the effect of obicetrapib/ezetimibe on coronary plaque characteristics.
McCarthy CP, Ballantyne CM, Blankstein R, et al. · Am Heart J 2025
- Projected impact of treatment intensification with statin, ezetimibe, and statin plus ezetimibe fixed-dose combination on MACE across six countries.
Farnier M, Santos RD, Cosin-Sales J, et al. · Eur J Prev Cardiol 2022
- Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021.
Katzmann JL, Kieble M, Enners S, et al. · Front Cardiovasc Med 2022
- Does tablet formulation alone improve adherence and persistence: a comparison of ezetimibe fixed dose combination versus ezetimibe separate pill combination?
Bartlett LE, Pratt N, Roughead EE · Br J Clin Pharmacol 2017
- Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India.
Shankar PK, Bhat R, Prabhu M, et al. · J Clin Lipidol 2007
Also in development for Lipidemia
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.